Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions

Details for Australian Patent Application No. 2004206856 (hide)

Owner Koster, H.

Inventors Yip, Ping; Grealish, Matthew Peter; Marappan, Subramanian; Koster, Hubert; Little, Daniel Paul; Siddiqi, Suhaib Mahmood; Hassman III, Chester Frederick

Agent Spruson & Ferguson

Pub. Number AU-B-2004206856

PCT Pub. Number WO2004/064972

Priority 60/441,398 16.01.03 US

Filing date 16 January 2004

Wipo publication date 5 August 2004

Acceptance publication date 7 September 2006

International Classifications

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

C07C 69/76 (2006.01) Esters of carboxylic acids

C07C 69/96 (2006.01) Esters of carboxylic acids

C07D 207/404 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 207/46 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 209/48 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 211/60 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 211/78 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 213/79 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 215/48 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

C07D 239/54 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 239/545 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 241/44 (2006.01) Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

C07D 261/12 (2006.01) Heterocyclic compounds having nitrogen and oxygen as the only ring hetero atoms

C07D 271/07 (2006.01) Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms

C07D 303/14 (2006.01) Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom

C07D 303/16 (2006.01) Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom

C07D 317/36 (2006.01) Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 405/10 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 495/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms

C07D 498/18 Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

4 August 2005 PCT application entered the National Phase

  PCT publication WO2004/064972 Priority application(s): WO2004/064972

1 June 2006 Assignment before Grant

  Koster, Hubert; HK Pharmaceuticals, Inc. The application has been assigned to Koster, Hubert

7 September 2006 Application Accepted

  Published as AU-B-2004206856

11 January 2007 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 19 Dec 2006. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

26 April 2007 Standard Patent Sealed

7 June 2007 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 04 Dec 2006

26 June 2008 Assignment Registered

  Koster, Hubert The patent has been assigned to caprotec bioanalytics GmbH

18 November 2010 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 20 Oct 2010. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

12 May 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 20 Oct 2010

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004206860-Compounds, compositions and methods

2004206853-Intradermal cellular delivery using narrow gauge micro-cannula